| 臺大學術典藏 |
2020-10-22T07:27:58Z |
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
|
Tha?i D.; Blauvelt A.; Reich K.; TSEN-FANG TSAI; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Hugot S.; You R.; Milutinovic M. |
| 臺大學術典藏 |
2020-10-22T07:27:53Z |
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1?year: Results from the CLEAR study
|
Blauvelt A.; Reich K.; TSEN-FANG TSAI; Tyring S.; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Hugot S.; You R.; Milutinovic M.; Tha?i D. |
| 臺大學術典藏 |
2020-10-22T07:27:50Z |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
|
Okada M.; Kirkham B.; Nash P.; Nash P.;Kirkham B.;Okada M.;Rahman P.;Combe B.;Burmester G.-R.;Adams D.H.;Kerr L.;Lee C.;Shuler C.L.;Genovese M.;Ahmed K.;Alper J.;Barkham N.;Bennett R.E.;Garc?A F.J.B.;Alonso R.B.;Blumstein H.B.;Brooks M.S.;Burmester G.-R.;Cagnoli P.;Caldron P.H.;Cantagrel A.;Chen D.-Y.;Churchill M.A.;Jr, Codding C.E.;Combe B.;Deane P.M.G.;Del Giudice J.;Deodhar A.A.;Dhar R.K.;Dokoupilova E.;Egan R.M.;Everding A.;Gal?Ndez E.;Genovese M.;Goddard D.H.;Gottlieb A.;Goupille P.;Griffin R.M.;Gupta R.C.;Hall S.;Hatti K.;Howell M.P.;Huang Y.-H.;Jajoo R.;Janssen N.M.;Kiltz U.;Kivitz A.J.;Klein S.J.;Korkosz M.P.;Kotha R.;Kremer J.M.;Lue C.;De La Fuente J.L.M.;Marzo-Ortega H.;Masmitja J.G.;Mease P.J.;Meroni P.L.;Mueller E.C.;Nandagudi A.C.;Nash P.;Fern?Ndez-Nebro A.;Neuwelt C.M.;Orbai A.M.;Oza M.R.;Parks D.L.;Pattanaik D.;Rell-Bakalarska M.E.;Rosmarin D.;Roussou E.;Rychlewska-Hanczewksa A.I.;Sikes D.H.;Stack M.T.;Sunkureddi P.;Tahir H.;Tha?I D.;Tsen-Fang Tsai;Turkiewicz A.M.;Unger L.;Cabello R.V.;Wagner U.;Wei C.-C.;Wells A.F.;Youssef P.;Zielinska A.; Korkosz M.P.; Klein S.J.; Kiltz U.; Kivitz A.J.; Janssen N.M.; Rahman P.; Combe B.; Burmester G.-R.; Adams D.H.; Kerr L.; Lee C.; Shuler C.L.; Genovese M.; Ahmed K.; Alper J.; Barkham N.; Bennett R.E.; Garc?a F.J.B.; Alonso R.B.; Blumstein H.B.; Brooks M.S.; Burmester G.-R.; Cagnoli P.; Caldron P.H.; Cantagrel A.; Chen D.-Y.; Churchill M.A.; Jr, Codding C.E.; Combe B.; Deane P.M.G.; Del Giudice J.; Deodhar A.A.; Dhar R.K.; Dokoupilova E.; Egan R.M.; Everding A.; Gal?ndez E.; Genovese M.; Goddard D.H.; Gottlieb A.; Goupille P.; Griffin R.M.; Gupta R.C.; Hall S.; Hatti K.; Howell M.P.; Huang Y.-H.; Jajoo R.; Zielinska A.; Wells A.F.; Youssef P.; Kotha R.; Kremer J.M.; Lue C.; de la Fuente J.L.M.; Marzo-Ortega H.; Masmitja J.G.; Mease P.J.; Meroni P.L.; Mueller E.C.; Nandagudi A.C.; Nash P.; Fern?ndez-Nebro A.; Neuwelt C.M.; Orbai A.M.; Oza M.R.; Parks D.L.; Pattanaik D.; Rell-Bakalarska M.E.; Rosmarin D.; Roussou E.; Rychlewska-Hanczewksa A.I.; Sikes D.H.; Stack M.T.; Sunkureddi P.; Tahir H.; Tha?i D.; TSEN-FANG TSAI; Turkiewicz A.M.; Unger L.; Cabello R.V.; Wagner U.; Wei C.-C. |
| 臺大學術典藏 |
2020-10-22T07:27:50Z |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
|
Okada M.; Kirkham B.; Nash P.; Nash P.;Kirkham B.;Okada M.;Rahman P.;Combe B.;Burmester G.-R.;Adams D.H.;Kerr L.;Lee C.;Shuler C.L.;Genovese M.;Ahmed K.;Alper J.;Barkham N.;Bennett R.E.;Garc?A F.J.B.;Alonso R.B.;Blumstein H.B.;Brooks M.S.;Burmester G.-R.;Cagnoli P.;Caldron P.H.;Cantagrel A.;Chen D.-Y.;Churchill M.A.;Jr, Codding C.E.;Combe B.;Deane P.M.G.;Del Giudice J.;Deodhar A.A.;Dhar R.K.;Dokoupilova E.;Egan R.M.;Everding A.;Gal?Ndez E.;Genovese M.;Goddard D.H.;Gottlieb A.;Goupille P.;Griffin R.M.;Gupta R.C.;Hall S.;Hatti K.;Howell M.P.;Huang Y.-H.;Jajoo R.;Janssen N.M.;Kiltz U.;Kivitz A.J.;Klein S.J.;Korkosz M.P.;Kotha R.;Kremer J.M.;Lue C.;De La Fuente J.L.M.;Marzo-Ortega H.;Masmitja J.G.;Mease P.J.;Meroni P.L.;Mueller E.C.;Nandagudi A.C.;Nash P.;Fern?Ndez-Nebro A.;Neuwelt C.M.;Orbai A.M.;Oza M.R.;Parks D.L.;Pattanaik D.;Rell-Bakalarska M.E.;Rosmarin D.;Roussou E.;Rychlewska-Hanczewksa A.I.;Sikes D.H.;Stack M.T.;Sunkureddi P.;Tahir H.;Tha?I D.;Tsen-Fang Tsai;Turkiewicz A.M.;Unger L.;Cabello R.V.;Wagner U.;Wei C.-C.;Wells A.F.;Youssef P.;Zielinska A.; Korkosz M.P.; Klein S.J.; Kiltz U.; Kivitz A.J.; Janssen N.M.; Rahman P.; Combe B.; Burmester G.-R.; Adams D.H.; Kerr L.; Lee C.; Shuler C.L.; Genovese M.; Ahmed K.; Alper J.; Barkham N.; Bennett R.E.; Garc?a F.J.B.; Alonso R.B.; Blumstein H.B.; Brooks M.S.; Burmester G.-R.; Cagnoli P.; Caldron P.H.; Cantagrel A.; Chen D.-Y.; Churchill M.A.; Jr, Codding C.E.; Combe B.; Deane P.M.G.; Del Giudice J.; Deodhar A.A.; Dhar R.K.; Dokoupilova E.; Egan R.M.; Everding A.; Gal?ndez E.; Genovese M.; Goddard D.H.; Gottlieb A.; Goupille P.; Griffin R.M.; Gupta R.C.; Hall S.; Hatti K.; Howell M.P.; Huang Y.-H.; Jajoo R.; Zielinska A.; Wells A.F.; Youssef P.; Kotha R.; Kremer J.M.; Lue C.; de la Fuente J.L.M.; Marzo-Ortega H.; Masmitja J.G.; Mease P.J.; Meroni P.L.; Mueller E.C.; Nandagudi A.C.; Nash P.; Fern?ndez-Nebro A.; Neuwelt C.M.; Orbai A.M.; Oza M.R.; Parks D.L.; Pattanaik D.; Rell-Bakalarska M.E.; Rosmarin D.; Roussou E.; Rychlewska-Hanczewksa A.I.; Sikes D.H.; Stack M.T.; Sunkureddi P.; Tahir H.; Tha?i D.; TSEN-FANG TSAI; Turkiewicz A.M.; Unger L.; Cabello R.V.; Wagner U.; Wei C.-C. |
| 臺大學術典藏 |
2019 |
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
|
Krueger J.G.; TSEN-FANG TSAI; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C.; Ryan C.; Crowley J.J.; Tha?i D.; Reich K.; Gooderham M. |
| 臺大學術典藏 |
2019 |
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study
|
Tha?I D.;Puig L.;Reich K.;Tsen-Fang Tsai;Tyring S.;Kingo K.;Ziv M.;Pinter A.;Vender R.;Lacombe A.;Xia S.;Bhosekar V.;Gilloteau I.;Guana A.;Blauvelt A.; Tha?i D.; Puig L.; Reich K.; TSEN-FANG TSAI; Tyring S.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Lacombe A.; Xia S.; Bhosekar V.; Gilloteau I.; Guana A.; Blauvelt A. |
| 臺大學術典藏 |
2019 |
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study
|
Tha?I D.;Puig L.;Reich K.;Tsen-Fang Tsai;Tyring S.;Kingo K.;Ziv M.;Pinter A.;Vender R.;Lacombe A.;Xia S.;Bhosekar V.;Gilloteau I.;Guana A.;Blauvelt A.; Tha?i D.; Puig L.; Reich K.; TSEN-FANG TSAI; Tyring S.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Lacombe A.; Xia S.; Bhosekar V.; Gilloteau I.; Guana A.; Blauvelt A. |
